Revolution Medicines Secures FDA Approval for RASONQUE, Triggers $250M Debt Tranche

Event Overview

On October 13, 2026, Revolution Medicines, Inc. filed a Form 8-K disclosing significant clinical, regulatory, and financing updates triggered on October 8, 2026.

Key Highlights

1. FDA Approval of RASONQUE™ (daraxonrasib):

   • The U.S. FDA approved RASONQUE™ for adult patients with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

2. Royalty Pharma Tranche A Term Loan Draw ($250.0 Million):

   • Under the June 23, 2025 Loan Agreement with Royalty Pharma Development Funding, LLC, the FDA approval triggered the advance and mandatory borrowing of the $250.0 million Tranche A Loan.
   • Loan Terms:
     • Interest Rate: Three-month Term SOFR (3.50% floor) + 5.75% per annum, payable quarterly in arrears.
     • Structure: Interest-only through maturity on October 8, 2032.
     • Fees: $5.0 million draw fee paid upon borrowing.
     • Prepayment: Prepayable in whole (not in part) with make-whole provisions and sliding prepayment premiums (3% prior to year 3, 1% prior to maturity).
   • Up to $500.0 million in additional debt tranches remains potentially available based on future milestones.

3. Election Regarding Tranche 3 Royalty Participation:

   • The FDA approval also triggered an option under the Revenue Participation Right Purchase and Sale Agreement with Royalty Pharma Investments 2019 ICAV.
   • Revolution Medicines held the option to sell an incremental revenue participation right for up to $250.0 million.
   • Company Decision: The Company elected not to exercise this option, avoiding revenue dilution on RASONQUE™ while preserving up to $500.0 million of future purchase price capacity under remaining milestones.

Market & Capital Structure Impact

• Commercial Validation: The commercial approval of RASONQUE™ marks a critical inflection point, validating the company's RAS-targeting platform in oncology.
• Balance Sheet Strength: The $250.0 million non-dilutive debt injection strengthens near-term cash reserves for commercial launch activities while the decision to decline the royalty sale demonstrates confidence in internal cash generation and asset valuation.